JACOBIO-B (01167) rose over 11% again, gaining 10.28% to HK$8.69 by the time of writing, with a turnover of HK$73.82 million. The company recently announced it had received an initial payment of RMB125 million from Oceanpine Capital under the capital increase and equity transfer agreements. This payment strengthens the group's cash reserves and supports the advancement of its innovative oncology therapy pipeline.

In October, JACOBIO-B disclosed agreements with Oceanpine Capital and an industrial partner for capital injection and equity transfer. Under the deal, Oceanpine Capital will acquire an 80% stake in Jacobio Rui Kang for RMB125 million upfront and an additional RMB75 million in milestone payments. Post-transaction, JACOBIO-B's stake in Jacobio Rui Kang will reduce to 10%. The company stated that this transaction aligns with its strategic focus on key oncology pipeline products targeting critical cellular pathways.